|
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
Oct 2023 |
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
Jan 2020 |
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
Jun 2023 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy |
May 2024 |
International Journal of Laboratory Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
Jun 2023 |
Haematologica |
Aplastic Anemia |
|
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
Dec 2023 |
Haematologica |
Aplastic Anemia |
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Consensus Recommendations for Severe Aplastic Anemia |
Aug 2024 |
Blood Advances |
Aplastic Anemia |
